BSE filing, NSE: LASA. Summary written from the filing by ALFA Finder's alert engine.
Lasa Supergenerics Ltd: key numbers
- Share price
- ₹4.67
- Market cap
- ₹23.40 Cr
- Revenue (annual)
- ₹25.14 Cr
- Net profit (annual)
- ₹-34.09 Cr
- P/E (TTM)
- -1.4×Sector 46.1×
- Promoter holding
- 53.65%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lasa Supergenerics Ltd
All →Lasa Supergenerics Other Announcement
Lasa Supergenerics Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure is a routine regulatory requirement.
Lasa Supergenerics Annual General Meeting
Lasa Supergenerics Limited held its 11th Annual General Meeting on September 30, 2026. Seven business items, including appointment of a director and borrowing powers, were discussed.
Lasa Supergenerics Annual Report
Lasa Supergenerics Ltd has submitted its 11th Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 30, 2026.
Lasa Supergenerics Annual General Meeting
Lasa Supergenerics Limited has issued a notice for its Annual General Meeting to be held on September 30, 2026, featuring seven agenda items.
Lasa Supergenerics Management Change
Mr. Ganesh Potdar has resigned as Additional and Whole-time Director of Lasa Supergenerics Limited, effective August 25, 2026. The company officially notified the exchanges.
Lasa Supergenerics Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Narrows
Lasa Supergenerics Ltd reported revenue from operations of ₹1.2 Cr (-94.0% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹3.6 Cr
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.